Oncology News | pharmaphorum

News

Numab raises $110m to develop cancer bispecific antibodies

Switzerland’s Numab has raised 100 million Swiss francs - around $110 million - in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HB

News

FDA review of Lilly/Innovent's sintilimab paves way for cut-...

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda.

News

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impress

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

News

NICE says no to Merck Serono's Bavencio in bladder cancer

Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to

Numab raises $110m to develop cancer bispecific antibodies

FDA review of Lilly/Innovent's sintilimab paves way for cut-...

BMS agrees deal worth up to $1.56bn for Agenus' TIGIT cancer...

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

Patients in England get fast access to AZ's Tagrisso in earl...

NICE says no to Merck Serono's Bavencio in bladder cancer

UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks